Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03015896
Recruitment Status : Recruiting
First Posted : January 10, 2017
Last Update Posted : March 25, 2021
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
David Bond, MD, Ohio State University Comprehensive Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021